- Report
- October 2024
- 181 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- August 2023
- 309 Pages
Global
From €2611EUR$2,750USD£2,202GBP
€5221EUR$5,500USD£4,404GBP
- Report
- February 2024
- 104 Pages
Asia Pacific
From €2520EUR$2,655USD£2,126GBP
€2801EUR$2,950USD£2,362GBP
- Report
- May 2021
- 250 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- August 2022
- 150 Pages
Global
From €5649EUR$5,950USD£4,765GBP
- Report
- October 2023
- 181 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- February 2024
- 120 Pages
Global
From €4509EUR$4,750USD£3,804GBP
The Rare Disease Genetic Testing market is a subset of the larger Genomics market. It focuses on the diagnosis and treatment of rare genetic diseases, which are caused by mutations in a single gene. These tests are used to identify the genetic cause of a disease, as well as to predict the risk of developing a disease in the future. They can also be used to identify the best treatment options for a particular patient.
The Rare Disease Genetic Testing market is growing rapidly, driven by advances in technology and the increasing availability of genetic testing services. This has enabled more accurate diagnosis and treatment of rare diseases, as well as the development of new treatments.
Companies in the Rare Disease Genetic Testing market include Ambry Genetics, Invitae, Counsyl, and GeneDx. Show Less Read more